Evaluation and Management of Women With BRCA1/2 Mutations

OncologyONCOLOGY Vol 19 No 11
Volume 19
Issue 11

Genetic counseling and testing for susceptibility to breast and ovariancancer is often an integral component of management for womenwith a personal and/or family history of these malignancies. In thisarticle, we will briefly review the function and genetic epidemiology ofthe two major susceptibility genes, BRCA1 and BRCA2. We will thenaddress approaches to risk assessment for women at high risk with respectto the probability that they harbor a deleterious mutation in oneof these genes, and the likelihood that they will develop cancer if sucha mutation is identified. The process of genetic counseling and testingis discussed, including a summary of the potential benefits, limitations,and risks of testing as well as a summary of test result interpretation.We conclude with a review and appraisal of the various options forbreast and ovarian cancer risk reduction and screening options forwomen with a BRCA1 or BRCA2 mutation.

Genetic counseling and testing for susceptibility to breast and ovarian cancer is often an integral component of management for women with a personal and/or family history of these malignancies. In this article, we will briefly review the function and genetic epidemiology of the two major susceptibility genes, BRCA1 and BRCA2. We will then address approaches to risk assessment for women at high risk with respect to the probability that they harbor a deleterious mutation in one of these genes, and the likelihood that they will develop cancer if such a mutation is identified. The process of genetic counseling and testing is discussed, including a summary of the potential benefits, limitations, and risks of testing as well as a summary of test result interpretation. We conclude with a review and appraisal of the various options for breast and ovarian cancer risk reduction and screening options for women with a BRCA1 or BRCA2 mutation.

It is estimated that between 5% and 10% of women with breast cancer have an inherited mutation in a cancer susceptibility gene.[1] Mutations in the BRCA1 and BRCA2 genes account for most of these cases. However, BRCA1/2 mutations are most likely to be identified in families with multiple cases of ovarian and earlyonset breast cancer.[2] The genetic basis of cancer in families in which multiple women have developed breast cancer, even at an early age, appears to be much more heterogeneous given that many do not harbor mutations in BRCA1 or BRCA2.[2] For example, one study found that among 237 families containing at least four cases of female breast cancer, only 65% were attributable to BRCA1 or BRCA2 mutations.[3] While other hereditary cancer syndromes also exist and should be considered based on suggestive family history constellations, together these account for only a small proportion of hereditary breast cancer. These syndromes, including Li-Fraumeni, Cowden, and Peutz-Jeghers, have distinct clinical features and are reviewed elsewhere.[4,5] Mutations in BRCA1, BRCA2, and the genes associated with the aforementioned syndromes all confer substantially elevated risks of breast and other cancers. But other genes have been identified that appear to confer more modest breast cancer risks, including ATM and CHK2, and their contribution to the genetic epidemiology of familial and hereditary breast cancer has yet to be fully elucidated.[2] Molecular and Population Genetics BRCA1 and BRCA2 function as tumor-suppressor genes and fall under the umbrella of "caretaker genes," given their role in DNA damage signaling and repair, transcriptional regulation, and cell-cycle regulation.[1] The BRCA1 gene is located on chromosome 17q21 and spans 5.6 kilobases of genomic DNA, comprising 1,863 amino acids.[1] BRCA2, on chromosome 13q12 is much larger, encompassing 10.2 kilobases and coding for 3,418 amino acids.[1] Given the large size of these genes, it is perhaps not surprising that over 1,500 distinct mutations and variants have been documented in each gene, including five rarely occurring genomic rearrangements in BRCA1 that are not detectable by sequencing.[6-8]. Some recurrent mutations have been identified in specific geographic or ethnic groups. Most notably, in Ashkenazi Jewish individuals (descended from central or eastern Europe), two BRCA1 mutations (187delAG, 5385insC) and one BRCA2 mutation (6174delT) have been identified with a population frequency of 1 in 40 (compared to the incidence in the general population of up to 1 in 500).[5,9] It is relatively rare for high-risk Jewish families to harbor a mutation other than one of these three.[10,11]

In the United States, virtually all clinical testing is performed by the commercial laboratory that holds the gene patents, Myriad Genetic Laboratories. As of February 2005, full gene sequencing of BRCA1 and BRCA2 costs approximately $3,000, and includes analysis for the five BRCA1 rearrangements. Testing for the three recurrent mutations observed in Ashkenazi Jews is $415, and single mutation analysis is $350. Many insurance companies will pay all or part of the costs of BRCA1/2 testing, usually on the basis of medical necessity to the person requesting testing. Risk Assessment A three-generation pedigree, as shown in Figure 1, is a convenient form of recording family history to determine whether an individual is at high risk of cancer. Age at diagnosis, current age, age and cause of death, surgical procedures (including those performed for benign conditions such as removal of the ovaries and uterus), precancerous conditions, and relevant environmental exposures should also be documented, as well as the ethnic/ racial background of the patient's grandparents (eg, "Irish"). Features of the family history that are suggestive of a BRCA1/2 mutation include the presence of (a) two or more women on the same side of the family diagnosed with breast cancer prior to age 50, (b) breast and ovarian cancer in the same woman, (c) breast and ovarian cancer in two or more relatives on the same side of the family, and (d) male breast cancer, especially with a family history of breast and/or ovarian cancer. In addition, Jewish women diagnosed with breast cancer (especially premenopausally) or ovarian cancer, even in the absence of a family history of these cancers, should be referred for genetic counseling and consideration of genetic testing. Mutations in the genes are passed down in an autosomal dominant fashion, such that each child of a parent with a BRCA1 or BRCA2 mutation has a 50% chance of also testing positive. Thus, it is important to assess family history on both the paternal and maternal side and to be aware that transmission of the mutated gene may occur through males. Specific referral guidelines, which may be useful in the identification of high-risk patients, have been developed.[12,13] Quantitative Assessments
Although a qualitative impression of risk is useful for making determinations about who may be referred for genetic counseling, quantitative assessments of carrier probability may be useful for patients who are considering BRCA1/2 testing, especially in light of the potential expense. The most easily referenced estimates are empiric, based on the reported family history of over 30,000 women tested clinically through Myriad Genetic Laboratories.[10,14] Data are organized into two easy-to-read tables, which may be downloaded onto palm or handheld personal computers. Probabilities of testing positive for a BRCA1 or BRCA2 mutation are provided based on whether or not the patient is of Ashkenazi Jewish ancestry, personal history of breast or ovarian cancer, and family history of these cancers by age at diagnosis of breast cancer (ie, less than age 50 or not). Important limitations of these data are the lack of independent verification of cancer diagnoses, and the fact that family history beyond that observed in first- and second-degree relatives may not have been routinely recorded. Other Risk Assessment Models
Other models for predicting BRCA1/2 carrier probability have been developed.[15] Thus far, only the BRCAPRO model has been subject to rigorous validation.[16] This model, which is available at no cost after completing a licensing agreement, can be downloaded from a comprehensive breast cancer risk assessment package known as CancerGene.[17] It relies on estimates of BRCA1/2 mutation prevalence and penetrance to apply Bayesian (a priori) probabilities of carrier status. Because a full-pedigree structure (of both affected and unaffected individuals, including all current ages, ages at diagnosis, and death) is required, providing rapid risk assessments at the time of the initial patient inquiry may not be feasible. Each model has its own set of strengths and limitations, and ease of use within the clinic. However, one critical caveat is that it is important for clinicians to always consider the limitations in pedigree-based risk assessment such as small family size, few females, limited family history information, and death at young ages. In addition, the decision to undergo genetic testing may not always be based merely on the likelihood of testing positive, but on the patient's worry about testing positive and the degree of reassurance, if any, that may be obtained as a result of pursuing testing. As discussed below, it is valuable to elicit these concerns during the course of genetic counseling. Genetic Counseling and Testing Although healthy individuals are often likely to seek out genetic counseling for the purposes of being tested themselves, it is ideal to initiate BRCA1/2 testing in the relative who is most likely to test positive on the basis of a personal history of ovarian cancer or early-onset breast cancer. In Figure 1, the proband (indicated by an arrow) is not the family member who is most likely to test positive, given that she was diagnosed with breast cancer after menopause. However, because there are no other living affected relatives available to test, it is still preferable to test her before testing healthy relatives concerned about their risk. Possible Outcomes of Testing
There are three possible outcomes of BRCA1/2 testing.[18] Again referring to Figure 1, it is possible that the proband will test positive for a deleterious mutation in the BRCA1 or BRCA2 gene. In that instance, there may be medical implications for her (as discussed later) and relatives such as her daughters and son (not pictured). Given that her maternal histo- ry is noncontributory, she would be counseled that her paternal relatives have a 50% chance of carrying the mutated gene (or 25% if they are children of her paternal uncles). Testing for these individuals would involve analysis only for the deleterious mutation. If they test negative for the familial mutation, they could be counseled that a true negative result means that their risk of developing cancer is thought to be equivalent to that of the general population, although personal risk factors and the cancer history of the other side of their family would also need to be assessed.

A third outcome of testing arises when no risk-conferring mutation in BRCA1 or BRCA2 is identified in the proband. This result is uninformative because it does not rule out the possibility that the proband still may have an inherited susceptibility to breast cancer, either due to a mutation that could not be detected by conventional methods or to a mutation in another gene. The probability of the former is estimated to be up to 15%.[8] In Figure 1, given the patient's later age at diagnosis, it is also possible that she may have developed sporadic breast cancer in a family that does in fact harbor a BRCA1 or BRCA2 mutation. Another type of uninformative result arises when a genetic variant or DNA change is identified that cannot be classified as deleterious or benign. In such instances, healthy relatives should not be tested for the variant for clinical purposes, as it does not serve to clarify their cancer risk. Counseling about cancer risk in "uninformative families" is complex and should be tailored to the specific history noted in the family.[18] Counseling and Consent
The genetic counseling and informed consent process should include a thorough discussion encompassing risk assessment, psychosocial assessment, and a review of test result inter- pretation, management guidelines, and family implications.[19] In addition, patients should consider the potential benefits, limitations, and risks associated with genetic testing. Fortunately, most studies have shown that at least in the context of genetic counseling and testing obtained in research settings, there do not appear to be significant adverse psychosocial effects among women who learn their results.[ 20] However, this does not diminish the potentially life-altering impact of genetic testing for an individual woman and her family, who may be faced with difficult decisions about screening and prevention as well as the various emotional responses to living with an increased cancer risk and the possible implications to future generations. Cancer RisksBreast and Ovarian Cancer
Cancer risks associated with mutations in BRCA1 and BRCA2 are quite variable depending on the population studied (Table 1).[3,21-31] Estimates from high-risk, registry-based kindreds and clinic-based populations have tended to yield the highest cancer risks of breast and ovarian cancer. For example, studies in such groups have found that the lifetime breast cancer risks in BRCA1 and BRCA2 carriers range from 73% to 87%.[21,22] The lifetime risk of ovarian cancer in BRCA1 carriers is approximately 40%, and in BRCA2 carriers, 25%.[3,21,22] Although data from unselected individuals (ie, those not studied on the basis of a strong family history of these malignancies) have revealed much lower estimates than those quoted above, a recent pooled analysis of data from 22 studies involving 8,139 index cases from unselected families demonstrated that the average risk of breast cancer was 65% in BRCA1 carriers and 45% in BRCA2 carriers.[23] The average cumulative risk of ovarian cancer was 39% and 11% in BRCA1 and BRCA2 carriers, respectively.[23] A novel approach to deriving cancer risk in carriers was undertaken by the New York Breast Cancer Study Group.[24] Instead of using "likelihood" approaches to estimating mutation status of relatives, BRCA1/2 testing was actually performed in relatives of unselected Jewish breast cancer patients with positive BRCA1/2 test results. The 71% cumulative risk of breast cancer to age 70 that they identified in carriers is comparable to that found in the highest-risk kindreds, as is the risk of ovarian cancer in BRCA1 carriers (46%).[24] The BRCA2 risk was lower, at 12% by age 70, although it increased to 23% by age 80.[24] There do appear to be differences in age-specific risks for breast and ovarian cancer between BRCA1 and BRCA2 carriers. Overall, the risk of breast and ovarian cancer among women under age 50 is lower in BRCA2 carriers than in BRCA1 carriers, but at all ages in both groups, the risk is significantly increased over that of the general population.[3,23] That said, ovarian cancer rarely occurs in women under age 30. Risk for this cancer begins to rise appreciably after age 35, throughout the 40s, and after age 50.[23] Second Malignancies After Breast Cancer
It is well established that BRCA1/2 carriers who have had unilateral breast cancer are at elevated risk of developing contralateral primary breast cancers. Studies have shown that the lifetime risk of such occurrences is between 40% and 65%, with the risk at 10 years postdiagnosis being as high as 30%.[21,22,25-27] By comparison, sporadic breast cancer patients face a 20-year cumulative risk of contralateral breast cancer of up to 20%.[28] With respect to the risk of metachronous ipsilateral breast cancer in carriers, the largest studies performed to date demonstrate that the 10-year actuarial risk is roughly between 11% and 14%, which is similar to the risk for young breast cancer patients without an identified inherited susceptibility.[ 27] Continued investigation in large cohorts over an extended period of time will be important to further clarify these risks and determine the incidence of late events. For women with early-stage breast cancer who have a good long-term prognosis, there is concern not only about the risk of a second breast cancer but also the risk of ovarian cancer. As expected, these patients have a very high 10-year actuarial risk of ovarian cancer after their diagnosis, which is approximately 13% in BRCA1 carriers and 7% in BRCA2 carriers.[29] In the cohort of stage I breast cancer patients studied by Metcalfe et al, 25% of their mortality over 10 years was attributed to ovarian cancer.[29] Therefore, management strategies in breast cancer patients need to emphasize the importance of aggressively addressing their risk of ovarian cancer. Other Cancers
The most substantial risks of cancer conferred by mutations in BRCA1 and BRCA2 are for breast and ovarian cancer. However, female mutation carriers should be informed that there are medical implications to at-risk male relatives with respect to prostate cancer and breast cancer.[30] Although the implications for screening are not clear, the risk of prostate cancer appears to be most significant in BRCA1 and BRCA2 carriers under age 65; however, the absolute risk is difficult to pinpoint.[30] In addition, other cancers have been reported to occur in excess, with overall low absolute rates (ie, less than 10%). For example, both BRCA1 and BRCA2 carriers have an increased risk of pancreatic cancer, whereas risks of melanoma, stomach cancer, and possibly other cancers appear to be elevated in BRCA2 carriers only.[21,25,30] Of note, by order of magnitude, the risk of fallopian tube cancer in BRCA1 and BRCA2 carriers is also quite significant (relative risk of 120, translating to a cumulative risk of 3%),[21] although pathologically, these cancers are very similar to ovarian cancers. Most studies have not shown an excess risk of colon cancer in carriers. Ongoing research will clarify the tumor spectrum associated with BRCA1/2 mutations. Summary
In the decade or so since the cloning of BRCA1 and BRCA2, an abundance of data have been published about cancer risk in BRCA1/2 carriers. While there are certainly some disparities in the estimated cancer risks, in many instances the confidence intervals within studies may be wide, and between studies, may overlap significantly. Patients should be informed about how cancer risks are derived and that precision in risk estimates is not possible. It is clear, however, that relative to the general population, BRCA1/2 carriers face significantly elevated risks of breast and ovarian cancer that need to be addressed through appropriate and aggressive management strategies. Risk ModifiersGenetic Factors
One potential explanation for the wide variability in cancer risks among mutation carriers is the effect of individual risk modifiers on penetrance. It is possible that specific mutations in BRCA1 or BRCA2 may have a different effect on risk based on their effect on the protein product or the location of the mutation within the gene.[32] For example, women with a mutation in the ovarian cancer cluster region (nucleotides 3059-4075 and 6503-6629) of the BRCA2 gene appear to have a higher risk of ovarian cancer and a diminished risk of breast cancer compared to women with mutations in other parts of the gene.[33,34] Variations in other genes are also important considerations. For instance, polymorphisms in genes that are related to the metabolism of sex hormones or DNA repair, such as the androgen receptor gene, AIB1, RAD51, and HRAS1, may affect risk in carriers, although the data are too preliminary to be utilized for tailored risk assessments in carriers.[32] Nongenetic Factors
Reproductive, environmental, and lifestyle factors may also affect risk in carriers. Rapid proliferation of breast epithelial cells occurs during puberty and pregnancy, which may result in the loss of somatic BRCA1 or BRCA2 alleles.[35] Thus, it is of interest to determine what impact reproductive factors such as parity, pregnancy, and breast-feeding have on cancer risk among carriers, especially given the tendency for high-risk women to develop premenopausal breast cancer. A neither strong nor consistent association of these risk factors with risk has emerged. Data are variable as to the effect of age at first full-term pregnancy, with some studies indicating no association and others suggesting a protective effect of late age at first full-term pregnancy.[36,37] Interestingly, data have shown that tubal ligation reduces the risk of ovarian cancer in BRCA1 but not BRCA2 carriers, and that this effect is magnified in carriers who also used oral contraceptives.[32] The specific mechanism by which tubal ligation may reduce risk has not been elucidated. Additionally, it is important to note that many of the studies examining the significance of cancer risk modifiers in mutation carriers are limited by small sample size and thus must be viewed as preliminary in nature.

  • Diet and Exercise-Many BRCA1/2 mutation carriers inquire about the effect of diet and exercise on breast cancer risk. Although there is an association between alcohol intake and breast cancer risk in the general population, there are no data about this or other dietary factors in carriers.[43] However, it has been postulated that given the genes' role in DNA repair, studies of drugs or nutritional supplements that reduce oxidative damage may be of interest.[32] One study showed that higher levels of physical activity during adolescence and having a normal weight at age 21 were associated with a delayed onset of breast cancer.[ 24] This area of modifiable risk factors, as with the others discussed above, will require further investigation before such information can be adequately considered in risk estimates or management guidelines. Nonetheless, given the other known health benefits of physical exercise, for example, it is reasonable to encourage women to pursue this activity.

Risk Management Suggested guidelines for risk management are summarized in Table 2. It is important to note that these guidelines serve as a general approach to management in BRCA1/2 carriers, which must be tailored and individualized based on each woman's age, current health, and preferences. Breast Cancer Screening
We recommend a multimodal approach to breast cancer screening, including monthly breast self-examination, clinician-performed breast exams (CBE) once or twice per year beginning at age 25, and annual mammography beginning at age 25, as well as consideration of screening breast magnetic resonance imaging (MRI).[12,44] We further recommend that women include a breast specialist in their regimen of breast exams. In addition, the interval of repeat mammography after a baseline mammogram, if performed prior to age 35, should be individualized based on the readability of these films, given the patient's breast density. These modalities are largely of unproven efficacy, although studies have assessed the role of mammography and other imaging techniques such as MRI. For example, the largest prospective study performed to date followed 1,909 high-risk women in the Dutch National Cancer Registry including 358 documented BRCA1/2 mutation carriers.[45] They underwent a CBE every 6 months along with annual mammography and MRI. The sensitivity for these three methods was 18%, 33%, and 80%, respectively, whereas the specificity was 98%, 95%, and 90%. Thus, screening MRI exams detected twice as many tumors as mammography, but the false-positive rates in the former were higher. Of note, within a median follow-up of approximately 3 years, 44 invasive cancers and 6 cases of ductal carcinoma in situ were detected. Overall, the cancers in the surveillance group tended to be of lower stage and histologic grade relative to controls. Other studies have also demonstrated that in BRCA1/2 carriers, MRI is more sensitive than mammography for detecting breast cancer, especially invasive cancers.[44] However, questions about mortality reduction as well as the utility and interval of screening with mammography and possibly ultrasound remain to be determined.[44] Despite these limitations, it is increasingly being recommended that mutation carriers undergo annual screening breast MRI. Studies have shown that mutation carriers have a high rate of developing interval cancers between yearly mammograms[46]; therefore, they may consider undergoing some form of imaging studies at 6-month intervals. Breast Cancer Risk Reduction
As discussed previously, women who test positive for a BRCA1 or BRCA2 mutation, including those who have had breast cancer, will reduce their risk of breast as well as ovarian cancer if they undergo oophorectomy prior to age 50.[42,47] Women age 35 or older who are not planning to become pregnant may also wish to consider the potential role of tamoxifen in reducing their breast cancer risk, although the efficacy in carriers-especially in BRCA1 carriers-is based on limited data.[39,41] In a number of clinical trials, aromatase inhibitors have been demonstrated to have a more profound effect than tamoxifen on reducing the risk of contralateral breast cancer.[48] However, no data exist concerning the extent to which these agents will reduce this risk in BRCA1/2 carriers. Ongoing studies are evaluating the efficacy of raloxifene (Evista), aromatase inhibitors, and other agents in reducing the risk of breast cancer in women at increased risk for breast cancer.[49] Some women with defined BRCA1/2 mutations may opt for prophylactic mastectomy. Studies in mutation carriers have consistently identified a risk reduction associated with prophylactic mastectomy to be on the order of about 90%. For example, the largest study performed to date was a multi-institutional case-control study of 105 BRCA1/2 carriers who underwent bilateral prophylactic mastectomy compared to 378 controls who did not.[50] The mean number of years of follow-up was 6.4 years. Overall, bilateral prophylactic mastectomy reduced the risk of breast cancer by about 90% in women who had not had oophorectomy, and by 95% in women who had undergone oophorectomy. A prospective study from the Netherlands demonstrated a similar risk reduction associated with prophylactic mastectomy.[51] Although many women in these studies had subcutaneous mastectomy for prophylaxis, this may not be the recommended procedure, given that a significant amount of residual tissue may remain. Thus, the preferred procedure may be a total mastectomy, and for many women, skin-sparing mastectomy is a suitable alternative.[50] The option of prophylactic mastectomy should be raised in all women who test positive for a BRCA1/2 mutation, and weighed against the potential efficacy of screening and other risk-reduction options. Of note, the rates of prophylactic mastectomy vary significantly by geographic location (eg, under 15% in the United States to over 50% in the Netherlands).[ 52] In part, women may be more inclined to consider such surgery based on psychological and/or medical considerations, such as anxiety about developing breast cancer, or if they have dense breasts or have had prior biopsies (especially those revealing atypia). Local Treatment Issues
Women with a new diagnosis of breast cancer who, in general, also have a strong family history of breast and/or ovarian cancer, may wish to consider genetic counseling and BRCA1/2 testing to help them make decisions about their definitive local treatment.[53] Although it is generally accepted that breast-conservation therapy with lumpectomy and radiation is an appropriate treatment option for mutation carriers,[27] such surgery does not address the risk of second primary breast cancers, namely those that may occur in the contralateral breast. Thus, some women who learn about positive genetic test results may opt for bilateral mastectomies to address this risk.[53] It behooves clinicians to identify women at high risk at the time of their breast biopsy, to give them ample opportunity to consider whether genetic testing will influence their decisionmaking. In addition, for patients who are undergoing adjuvant chemotherapy prior to the initiation of radiation therapy, an expanded window of time is available to consider the possibility of BRCA1/2 testing. Research is under way to determine the optimum time to offer BRCA1/2 testing to breast cancer patients, and what the impact is on quality of life, psychosocial outcomes, and surgical decisionmaking. Ovarian Cancer Screening and Risk Reduction
At present, BRCA1/2 carriers who are not inclined to have their ovaries removed are advised to consider the available screening options, which consist of pelvic exams beginning at age 25, and by age 30 to 35, transvaginal ultrasounds with color Doppler as well as CA-125 blood tests every 6 months.[12,46] Initial data suggest that tracking CA-125 levels longitudinally and calculating the risk of ovarian cancer using a specified algorithm may improve the sensitivity of this measure.[54] Overall, however, the prospects of early detection with the approach mentioned are limited, and most women who get diagnosed with ovarian cancer are not identified at an early stage.[55-57] The development of more highly sensitive and specific measures for ovarian cancer screening is an active area of research.[57] In light of the very high risk of ovarian cancer associated with BRCA1/2 mutations, and the lack of effective measures for early detection, carriers are strongly recommended to undergo prophylactic bilateral salpingo- oophorectomy when childbearing is completed.[12,46] Overall, the rates of prophylactic oophorectomy, both in the United States and abroad, range from 13% to 78% and thus are higher than those for prophylactic mastectomy.[ 52] In the largest study of this strategy to date, Rebbeck et al examined 259 carriers who underwent oophorectomy vs 292 matched controls who had not.[42] Over a mean follow-up of approximately 8 years, 4% of carriers in the oophorectomy group developed papillary serous peritoneal cancer.[42] A smaller prospective study in a single institution with shorter followup revealed that oophorectomy was associated with a lower risk reduction (85%).[47] As documented in earlier case reports, peritoneal carcinomatosis may develop after oophorectomy; this is treated as a late-stage ovarian cancer.[47] In addition, in the largest studies performed to date, occult ovarian cancer discovered at the time of oophorectomy occurred at a rate of about 2.5%.[58] In light of this finding, a protocol involving rigorous operative procedures and pathologic examination for women undergoing oophorectomy has been suggested. This approach increases the detection rate of occultcarcinomas, potentially affecting subsequent medical management.[58]

  • Surgical Procedure-With respect to the surgical procedure itself, bilateral salpingo-oophorectomy should be performed, given the very high risk of fallopian tube cancer in BRCA1/2 carriers.[21,47] For most women, this surgery may be performed laparoscopically with a low rate of complications.[47] Although some women may elect to undergo a hysterectomy concomitant with salpingo- oophorectomy, there is not enough evidence to recommend this procedure based on concerns solely related to a possible slightly increased risk of endometrial cancer in carriers (eg, primary uterine papillary serous cancer), the associated risk of uterine cancer in women who opt to take tamoxifen, or concerns that the fallopian tubes may be completed excised only by removal of the uterus.[56] For many young women, the most significant implication of oophorectomy is the induction of surgical menopause. Although nonhormonal alternatives may provide symptomatic relief for many women, some mutation carriers may wish to consider hormone replacement therapy until age 50. However, limited data exist on the impact of such therapy on the subsequent risk for breast cancer.[42] Mutation carriers should, therefore, be carefully counseled regarding the use of such therapy.[59] It is also important to advise women undergoing premature menopause secondary to prophylactic oophorectomy about the importance of being monitored and treated for sequelae such as osteoporosis and heart disease.

Conclusions In summary, over the past decade, significant strides have been achieved in the evaluation and management of individuals with hereditary breast cancer. The care of these women involves a multidisciplinary group of clinicians including genetic counselors, nurses, surgeons, medical oncologists, gynecologists, primary care physicians, and radiologists. Decisions regarding prevention and screening strategies must be individualized, and each woman should be encouraged to take the time to fully weigh the implications of different management approaches prior to deciding on a particular plan.


Dr. Isaacs has received financial support from Swing Fore the Cure. The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.


1. Phillips KA: Current perspectives on BRCA1- and BRCA2-associated breast cancers. Intern Med J 31:349-356, 2001.
2. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676, 2004.
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998.
4. Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 23:276- 292, 2005.
5. Eng C, Hampel H, de la Chapelle A: Genetic testing for cancer predisposition. Ann Rev Med 52:371-400, 2001.
6. Breast Cancer Information Core. Available at http://research.nhgri.nih.gov/bic/. Accessed August 24, 2005.
7. Unger MA, Nathanson KL, Calzone K, et al: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841-850, 2000.
8. BRACAnalysis Technical Specifications. Myriad Genetic Laboratories, Updated August 29, 2005. Available at www.myriadtests.com/ provider/doc/tech_specs_brac.pdf. Accessed August 29, 2005.
9. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997.
10. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002.
11. Kauff ND, Perez-Segura P, Robson ME, et al: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39:611-614, 2002.
12. National Comprehensive Cancer Network: Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology, version 1.2005. Available at www.nccn.org/professionals/physician_gls/ PDF/genetics_screening.pdf. Accessed August 24, 2005.
13. Hampel H, Sweet K, Westman JA, et al: Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet 41:81-91, 2004.
14. Myriad Genetic Laboratories: Mutation prevalence tables for BRCA1/2 genes. Available at www.myriadtests.com/provider/ mutprev.htm. Accessed August 24, 2005.
15. Marroni F, Aretini P, D’Andrea E, et al: Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278-285, 2004.
16. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002.
17. CancerGene. Available at www. utsouthwestern.edu/utsw/cda/dept47829/files/ 65844.html. Accessed August 24, 2005. 18. Peshkin BN, DeMarco TA, Brogan BM, et al: BRCA1/2 testing: Complex themes in result interpretation. J Clin Oncol 19:2555-2565, 2001.
19. Trepanier A, Ahrens M, McKinnon W, et al: Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 13:83-114, 2004.
20. Braithwaite D, Emery J, Walter F, et al: Psychological impact of genetic counseling for familial cancer: A systematic review and metaanalysis. J Natl Cancer Inst 96:122-133, 2004.
21. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002.
22. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994.
23. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003.
24. King MC, Marks JH, Mandell JB and the New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003.
25. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999.
26. Metcalfe KA, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004.
27. Robson M, Svahn T, McCormick B, et al: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer 103:44-51, 2005.
28. Dawson LA, Chow E, Goss PE: Evolving perspectives in contralateral breast cancer. Eur J Cancer 34:2000-2009, 1998.
29. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risks of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222-226, 2005.
30. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 22:735-742, 2004.
31. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1975- 2000. Bethesda, Md, National Cancer Institute. Available at http://seer.cancer.gov/csr/ 1975_2002. Accessed August 24, 2005.
32. Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113-123, 2002.
33. Thompson D, Easton D, Breast Cancer Linkage Consortium: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001.
34. Al-Saffar M, Foulkes WD: Hereditary ovarian cancer resulting from a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: Is the OCCR useful clinically? J Med Genet 39:e68, 2002.
35. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713, 2001.
36. Jernstrom H, Lubinski J, Lynch HT, et al: Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094-1098, 2004.
37. Hartge P, Chatterjee N, Wacholder S, et al: Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiol 13:255-261, 2002.
38. Narod SA, Dube MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002.
39. Narod SA, Brunet J-S, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356:1876-1881, 2000.
40. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002.
41. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001.
42. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-22, 2002.
43. Nkondjock A, Ghadirian P: Epidemiology of breast cancer among BRCA mutation carriers: An overview. Cancer Lett 205:1-8, 2004.
44. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004.
45. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004.
46. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002.
47. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.
48. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619- 629, 2005.
49. Dunn BK, Wickerham DL, Ford LG: Prevention of hormone-related cancers: Breast cancer. J Clin Oncol 23:357-367, 2005.
50. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004.
51. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001.
52. Wainberg S, Husted J: Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989-1995, 2004.
53. Schwartz MD, Lerman C, Brogan B, et al: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22:1823-1829, 2004.
54. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 353:1207- 1210, 1999.
55. Liede A, Karlan BY, Baldwin RL, et al: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20:1570-1577, 2002.
56. Karlan BY: Defining cancer risks for BRCA germline mutation carriers: Implications for surgical prophylaxis (editorial). Gynecol Oncol 92:519-520, 2004.
57. Modugno F, Ovarian Cancer and High- Risk Women Symposium Presenters: Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 91:15-31, 2003.
58. Powell CB, Kenley E, Chen LM, et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127-132, 2005.
59. Garber JE, Hartman AR: Prophylactic oophorectomy and hormone replacement therapy: Protection at what price? (editorial) J Clin Oncol 22:978-980, 2004.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Related Content